RFX2

Across TCGA pan-cancer cohorts, RFX2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RFX2 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher RFX2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RFX2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, ACC, and CESC are the cancer types where RFX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
ACC	OS	Median	All	0.188	0.820	<.001	12	view →
CESC	DFS	Median	II,III,IV	0.146	0.705	.010	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.972	0.828	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RFX2–DLBC (DFS)

Open the DLBC breakdown →